French health authorities are expanding vaccine coverage for children to address a recent rise in invasive meningococcal infections. A temporary catch-up vaccination program is now available for children born in 2020, 2021, and 2022, covering vaccines against meningococcal groups B and ACWY. This move comes as France continues to strengthen its national immunization strategy, particularly following the implementation of mandatory vaccination for children born in 2023.
The decision to extend coverage, with a reimbursement rate of 65% and approval for local authorities, is based on recommendations from the Haute Autorité de Santé (HAS) issued on March 13th and July 17th, 2025. This builds on a previous extension of coverage for the Nimenrix vaccine, announced in early March 2026, as reported by Vidal. The program specifically targets children who were not initially subject to the mandatory vaccination requirements.
The increase in invasive meningococcal infections (IIM) observed in 2023 and 2024 prompted the HAS to re-evaluate vaccination protocols. Since January 2025, vaccination against meningococcal groups ACWY and B has been mandatory for all children born from that date onward, representing a significant step in protecting the youngest members of the population. This catch-up program aims to bridge the gap for those born in the preceding years.
Understanding the Vaccines: Menveo and Bexsero
The expanded coverage includes two key vaccines: Menveo and Bexsero. Menveo is approved for use in individuals aged two years and older, protecting against meningococcal serogroups A, C, W-135, and Y. Bexsero, is indicated for individuals from two months of age, offering protection against group B Neisseria meningitidis. Both vaccines are designed to prevent invasive disease caused by these potentially life-threatening bacteria.
For children over the age of two who have not previously received vaccination against meningococcal groups B and ACWY – including those who have only been vaccinated against serogroup C – the recommended catch-up schedule is straightforward. A single dose of vaccine is sufficient for protection against ACWY, while two doses of Bexsero, spaced one month apart, are recommended for protection against group B.
Why This Catch-Up Program?
Meningococcal disease is a serious bacterial infection that can lead to meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (blood poisoning). Early symptoms can resemble the flu, making prompt diagnosis and treatment crucial. The disease can progress rapidly and cause severe complications, including brain damage, hearing loss, and even death. The World Health Organization provides comprehensive information on the disease and its prevention.
The recent resurgence of invasive meningococcal infections in France underscored the need for proactive measures. While the mandatory vaccination program for newborns in 2023 is expected to have a long-term impact, the catch-up program addresses the vulnerability of older children who were not initially included in the mandatory schedule. This targeted approach aims to quickly increase population immunity and reduce the risk of outbreaks.
What Parents Need to Know
Parents of children born in 2020, 2021, and 2022 are encouraged to consult with their pediatrician or family doctor to determine if their child is eligible for the catch-up vaccination program. The program is designed to be easily accessible, with the vaccines covered by the national health insurance system.
It’s important to note that this is a temporary program, specifically designed to address the current epidemiological situation. The HAS will continue to monitor infection rates and adjust vaccination recommendations as needed. Staying informed about the latest public health guidance is essential for protecting children from preventable diseases.
The French Ministry of Health provides detailed information on vaccination schedules and recommendations on its website. Parents can also find answers to frequently asked questions and locate vaccination centers in their area.
Disclaimer: This article provides general information about the expanded vaccination program and should not be considered medical advice. Always consult with a qualified healthcare professional for personalized guidance on vaccination decisions.
The next update regarding the program’s impact and potential adjustments to the national vaccination schedule is expected from the HAS in the fourth quarter of 2025. We will continue to monitor developments and provide updates as they become available. Share your thoughts and questions in the comments below.
